Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;
Department of Laboratory Medicine and Pathology, University of Minnesota Health, Minneapolis, MN;
Clin Chem. 2016 Jun;62(6):824-30. doi: 10.1373/clinchem.2015.250514. Epub 2016 Mar 28.
We assessed the impact of clinical decision support (CDS) rules within the electronic health record for ionized calcium (iCa), serum magnesium (Mg), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in intensive care unit (ICU) inpatients at a large academic center.
A repeat order for measurement of iCa or Mg placed within 24 (iCa) or 48 (Mg) h of a previously nonactionable result, or additional orders for NT-proBNP beyond 1 within a single hospitalization, triggered a CDS pop-up alert showing the prior result and offering the opportunity to cancel the order or to place the order after entering an indication for repeat testing. The number of tests performed for each of these analytes and incidence of adverse clinical outcomes potentially associated with hypocalcemia or hypomagnesemia were compared between the 90-day period before CDS implementation and two 90-day periods immediately following.
iCa test volumes decreased by 48%, Mg by 39%, and NT-proBNP by 28% in the 90-day period immediately following implementation and remained decreased by 54%, 49%, and 22%, respectively, during the following 90-day period (all P values <0.0002). Adverse clinical outcomes potentially associated with hypocalcemia or hypomagnesemia did not increase (all P-values >0.17).
Implementation of CDS dramatically decreased repeat testing of iCa, Mg, and NT-proBNP without adversely impacting clinical outcomes in the ICU. Expansion of the rules from the ICU units to include the entire hospitalized patient population and expansion to additional analytes is expected to lead to further reductions in testing.
我们评估了电子病历中离子钙(iCa)、血清镁(Mg)和 N 端脑利钠肽前体(NT-proBNP)的临床决策支持(CDS)规则在大型学术中心的重症监护病房(ICU)住院患者中的影响。
在先前无作用结果的 24 小时(iCa)或 48 小时(Mg)内重复测量 iCa 或 Mg,或在单次住院期间超过 1 次重复测量 NT-proBNP,会触发 CDS 弹出警报,显示先前的结果,并提供取消订单或在输入重复测试指征后下达订单的机会。在 CDS 实施之前的 90 天和之后的两个 90 天期间,比较了这些分析物的测试数量和潜在与低钙血症或低镁血症相关的不良临床结果的发生率。
在实施后的 90 天内,iCa 测试量减少了 48%,Mg 减少了 39%,NT-proBNP 减少了 28%,在随后的 90 天内,iCa、Mg 和 NT-proBNP 的测试量分别减少了 54%、49%和 22%(所有 P 值<0.0002)。与低钙血症或低镁血症相关的不良临床结果并未增加(所有 P 值>0.17)。
CDS 的实施显著减少了 iCa、Mg 和 NT-proBNP 的重复检测,而不会对 ICU 中的临床结果产生不利影响。将规则从 ICU 扩展到包括整个住院患者群体,并扩展到其他分析物,预计将进一步减少检测。